Modern Medicine and Pharmaceutics by Purusotam Basnet
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1 
Modern Medicine and Pharmaceutics 
Purusotam Basnet 
Drug Transport and Delivery Research Group, Department of Pharmacy;  
In vitro Fertilization Laboratory, Department of Obstetrics and Gynaecology, 
University Hospital of North Norway and Women’s Health and Perinatology  
Research Group, Department of Clinical Medicine,  
University of Tromsø, Tromsø,  
Norway 
1. Introduction  
There are evidences that people have been using medicine to cure illness from the early 
civilization in Africa, Asia and Europe. The wide varieties of treatments such as Shamanism, 
surgery and drug formulations have been practiced. The drug materials from the plants, 
animals, minerals were used for the medicinal purposes, are referred today as “Crude 
Drugs”. As knowledge on disease and drugs is expanded further and more purified form of 
the materials were chosen to prepare further effective drugs and medicines. As the 
development of modern societies immersed in the world, two different philosophical 
approaches in the field of medicinal treatment came forward. In the Eastern societies such as 
in China and India, holistic approaches were adopted. In these societies, disease or illness is 
considered as an integral part of the body and can be corrected with the selected foods or 
formulation of crude drugs mainly derived from plants and a few from animals or minerals 
together with the body adoptation. But in contrast, in the Western society, disease is 
considered as the separate entity from the body and can be eliminated by surgery or using 
particular chemical substance. Especially in the western medicine, the practice of using 
purified form or pure chemical substances is developed. The knowledge on chemical 
sciences especially synthetic chemistry and purification techniques were rigorously 
developed to fulfil the need of chemical substance. This led to not only the foundation for 
the development of science and technology but also the concept of industrialization came 
forward.  
In general, pure chemical substance is not administered directly to the disease condition to 
cure or treat the disease. Depending on the disease condition and chemical nature of the 
drug substance, several kinds of formulation and route of administration are in practice. 
Therapeutic effect of the drug substance will only be achieved, if the right chemical 
substance with sufficient amount be delivered in the targeted tissue sites for the sufficient 
length of time in the person having pathophysiological condition. Formulations play great 
roles in distributing drugs in the body. Moreover, according to the type and condition of the 
disease, same drug substance might provide separate therapeutic effects based on the types 
of formulation, route and interval of administrations. In general, the term ‘drug’ represents 
pharmacologically active chemical substance. Pharmaceutical sciences provide the 
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knowledge and technique to utilize the drug substance for the effective therapy. In recent 
years, because of the advancement in pharmaceutical sciences, several drug substances are 
better utilized for the health benefit. Pharmaceutical industries contributed enormously for 
the advancement of modern medicine together with the development of particular the 
formulation for desired route of administration in order to obtain optimum therapeutic 
value of the drugs substance. 
2. Historical overview on the development of modern drugs 
In fact, many of the drug substances which are used today commercially have certain 
historical links to the traditional uses. Among them, the history of morphine and acetyl 
salicylic acid (aspirin) are widely discussed and well documented.  
There are evidences of using latex of opium plant (Papaverum somniferum) in Chinese 
traditional medicine, Ayurveda, and Ancient Greek medicine to relieve pain. The desire to 
obtain more effective and purer drug has always been remained as the deep thrust in 
human nature. The first report of morphine purification was made by Derosne in 1803 and 
further detail was published by Seguin in 1814. (Derosne, 1803; Seguin, 1814). A German 
pharmacist, Sertürner claimed the first purification of active compound from opium latex 
and published in 1805, later it was found that the isolated compound was not an alkaline 
narcotic component rather it was identified as meconic acid (Sertürner, 1805; 1806). On 
continuing, Sertürner extracted the opium poppy latex with hot water and precipitated with 
ammonia and obtained a pure crystalline compound having narcotic properties of opium 
(Sertürner, 1817). The compound was named as morphine (1) and structure was confirmed 
later. In 1874, Wright reported heroin (2), a diacetyl derivative of morphine (Wright, 1874), 
and it was commercialised by Bayer AG in 1898. Because of the strong narcotic properties, 
heroin was banned for the therapeutic use but morphine and codeine (3), another derivative 
of morphine, are still very important commercial drugs today after almost 200 years of their 
discovery (Figure 1).  
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Fig. 1. Structure of morphine and its derivatives. 
After extraction and purification of morphine, the technique was applied to isolate other 
important alkaloids and they were commercialized immediately. In 1817, Pelletier and co-
worker reported emetine (4) from Ipecacuanha and strychnine (5) from Strychnos (Pelletier, 
1817). In 1820, same group reported the isolation of quinine (6) from Cincona species 
(Pelletier, 1820) which was commercialized as the anti-malarial drug. Other important 
alkaloids such as brucine (7) and caffeine (8) in 1819, colchecin (9) in 1920, codeine (3) in 
1833, atropine (10) in 1848 were isolated (Nicolaou & Montagnon, 2008). The complete 
structures of many of these compounds were confirmed later. Coniine (11) was isolated in  
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Fig. 2. Structure of alkaloids having therapeutic and commercial uses. Discovery of these 
alkaloids led to the foundation for the modern medicine and industrialisation. 
1826, complete structure was elucidated in 1870 and later synthesized in 1881. All these 
drugs with almost of 200 years of history are still used in commercial scale (Figure 2) 
(Newman, 2010). 
Another important modern drug with long history and widely discussed molecule is acetyl 
salicylic acid (aspirin) (13). In spite of development of several effective antipyretic drugs the 
importance of aspirin has never been diminished.  
Acetylsalicylic acid (13), an acetyl-derivative of salicylic acid (14), is a mild, non-narcotic 
analgesic. It is useful in the relief of headache and muscle and joint aches. The drug works 
by inhibiting prostaglandins production which sensitizes nerve endings to pain. The 
discovery of aspirin (13) is linked to 14, salicyl aldehyde (15) and salicin (16), a chemical 
component derived from the bark of Willow tree.  
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Fig. 3. Structure of aspirin and other related compounds. Salicin, a compound isolated from 
the bark of Willow tree led to the discovery of aspirin. 
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Hippocrates (460-377 B.C.), the father of modern medicine, described the prescription of 
using the powder made from the bark of the willow tree for the treatment of headaches, 
pains and fevers. By 1829, scientists discovered that the pain relieving compound as salicin 
(16) in willow plants. The active ingredient in willow bark was isolated by Johann Buchner, 
a tiny amount of bitter tasting yellow, needle-like crystals, which he called salicin. Two 
Italians, Brugnatelli and Fontana, had in fact already obtained salicin in 1826, but in a highly 
impure form. In 1829, Henri Leroux had extracted salicin, in crystalline form for the first 
time, and in 1839, Raffaele Piria succeeded in obtaining the salicylic acid by oxidation (Piria, 
1839) (Figure 3). Although salicylic acid was found with analgesic and antipyretic 
properties, its strong side effect of stomach upsetting could not be utilized clinically. A 
French chemist, Charles Frederic Gerhardt in 1853, neutralized the side effect of salicylic 
acid by buffering it with sodium hydroxide (sodium salicylate) and acetyl chloride, creating 
acetylsalicylic acid. Gerhardt's discovery could not be commercialized (Gerhardt, 1853; 
Nicolaou & Montagnon, 2008). 
In 1899, a German chemist, Felix Hoffmann, who worked for Bayer, rediscovered Gerhardt's 
formula. Felix Hoffmann made the formula for the treatment of his father who was suffering 
from the pain of arthritis. With good results, Bayer marketed the new wonder drug 
(Nicolaou & Montagnon, 2008). Aspirin was patented on February 27, 1900. The name 
Aspirin was given to- ‘A’ for acetyl, the "spir" for Spiraea ulmaria (source of salicylic acid) 
and 'in' for ending name for medicine. 
 
Table 1. A list of some important modern medicines in chronological order of discovery 
with therapeutic uses. 
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In the beginning, aspirin was sold in the powder form but in 1915, the first aspirin tablets 
were marketed. Aspirin and heroin were once trademarks of Bayer. After Germany lost 
World War I, Bayer was forced to give up both trademarks as part of the Treaty of Versailles 
in 1919 (Belis, 2012).  
In addition to morphine and aspirin, there are several other chemical substances which 
initiated the industrialization and changed our social structure due to the development of 
corporate culture and globalization trends for the discovery of modern medicine. A list of 
some important drugs with their therapeutic uses and chronological order of discovery are 
given in Table 1.  
3. Pharmaceutical Industry 
3.1 Development of pharmaceutical industry 
Merck in Germany was possibly the earliest company founded in Darmstadt in 1668. In 
1827, Heinrich Emanuel Merck began the transition towards an industrial and scientific 
concern, by manufacturing and selling alkaloids (Merck Group History, 2012). 
GlaxoSmithKline’s origins can be traced back to 1715, it was only in the middle of the 19th 
century that Beecham became involved in the industrial production of medicine, producing 
patented medicine from 1842, and the world’s first factory for producing only medicines in 
1859 (GSK History, 2012).  
In the USA, Pfizer was founded in 1849, by two German immigrants, initially as a fine 
chemicals business. They expanded rapidly during the American civil war as demand for 
painkillers and antiseptics rocketed (Pfizer History, 2012). Whilst Pfizer was providing the 
medicines needed for the Union war effort, a young cavalry commander named Colonel Eli 
Lilly was serving in their army. A trained pharmaceutical chemist, Lilly was an archetype of 
the dynamic and multi-talented 19th century American industrialist, who set up a 
pharmaceutical business in 1876 and was a pioneer of new methods in the industry, being 
one of the first to focus on R&D as well as manufacturing.  
Pharmaceutical industries grew rapidly in number and size after the advancement of basic 
knowledge on the isolation and purification of chemical component from the crude drugs. 
In the meantime, it encouraged to the development of synthetic chemistry. The 
pharmacological properties of pure compound obtained either from isolation from natural 
resources or synthesized in the laboratories were studied. The public and private 
investments were carried on pharmaceutical industry and drug market expanded rapidly. 
The pharmaceutical industries established in the early history are still continuing today and 
their economic impact in the development of country is extremely crucial. Some of the 
pharmaceutical industries which initiate some important drugs in the early development of 
modern medicine are listed as in the Table 2. 
3.2 Economic impact of the pharmaceutical industry 
Today, the revenue collection by big pharmaceutical industry is bigger than that of national 
budge of many small and poor nations. Based on the revenue collection, top ten 
pharmaceutical industries are listed in Table 3 (Roth et al., 2010). Because of the huge 
investment of pharmaceutical industries, it led to open the research and development of  
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Table 2. Chronological order of commercialization of some important modern drugs. 
further understanding in human biology and medicine. In the meantime, it is also partly 
responsible to widen the gap between rich and poor which made unstable and unhappy 
society. In term of wealth, these top pharmaceutical industries are able to challenge the 
whole nation and have power to change the social structure.  
Top 10 pharmaceutical industries account for 59.40% of total revenue of the top 50 
pharmaceutical companies. In the same top 20 pharmaceutical industries accounts for 
81.53% of total revenue of the top 50 pharmaceutical companies. Therefore the global drug 
markets are dominated by a few large pharmaceutical industries. Several small 
pharmaceutical industries in developing countries are only able to produce generic drugs 
and their impact in the global market is negligibly small.  
 
 
Table 3. Top twenty pharmaceutical companies based on 2010 revenues (in million USD). 
Pharmaceutical Industry                           Revenue (Millions USD)
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3.3 The most industrialized drugs 
Each year new and more effective drugs come into the market and they replace previous 
drugs. There is hard completion among the pharmaceutical industries to make more profit 
for their industry. In addition, some drugs because of unreported side effects, they have to 
be withdrawn from the market. Therefore it is difficult to stand top selling drug of all the 
time. According to revenue collection, a list of top ten selling drugs is listed in Table 4 (Top 
ten selling drug, 2011). The revenue obtained by selling single drug is much higher than that 
of a national budget of a small and poor country. 
 
Drug name Treatment for Produced by Sale 
(billions) 
1. Lipitor 
(Atorvastatin) 
Statin i.e., a cholesterol-lowering drug.  
Lowers LDL cholesterol and triglyceride levels 
Pfizer  13.5 
2. Plavix 
(Clopidogrel) 
Inhibits blood clots in arteries such as coronary, 
carotid and peripheral arteries of the limbs and 
prevents ischemia and thrombosis 
Bristol-
Myers 
Squibb & 
Sanofi-
Aventis  
7.3  
3. Nexium 
(Esomeprazole) 
A proton pump inhibitor (H+/K+-ATPase enzyme) 
which is used in the treatment of dyspepsia, peptic 
ulcer disease, gastro esophageal reflux disease.  
AstraZeneca 7.27  
4. Seretide/ 
Advair 
(Fluticasone+ 
salmeterol) - 
It is a bronchodilator which relaxes the muscles in 
the walls of the small air passages in the lungs. 
GlaxoSmith
Kline 
7.1 
5. Enbrel 
(Etanercept) 
A tumor necrosis factor (TNF)-blocker, is widely 
used in immune diseases (rheumatoid arthritis, 
juvenile idiopathic arthritis, ankylosing 
spondylitis, psoriatic arthritis, plaque psoriasis) 
and reduce inflammation.  
Amgen and 
Wyeth 
5.3  
6. Zyprexa 
(Olanzapine) 
An atypical antipsychotic used in the treatment of 
schizophrenia, depressive episodes associated 
with bipolar disorder, acute manic episodes and 
maintenance treatment in bipolar disorder.  
Eli Lilly 5.3  
7. Risperdal 
(Risperidone) 
Risperidone is an antipsychotic used to treat 
schizophrenia including adolescent schizophrenia, 
the mixed and manic states associated with bipolar 
disorder, and irritability in children with autism.  
Janssen-
Cilag 
4.9  
8. Seroquel 
(Quetiapine) 
An antipsychotic used in the management of 
schizophrenia and bipolar I disorder, including 
insomnia and anxiety disorders.  
Astra 
Zeneca 
4.6  
9. Singulair 
(Montelukast 
sodium) 
A leukotriene receptor antagonist used in the 
treatment of asthma and to relieve symptoms of 
seasonal allergies.  
Merck & 
Co., Inc 
4.5  
10. Aranesp 
(Darbepoetin 
alfa) 
A synthetic form of erythropoietin which 
stimulates erythropoiesis to treat anemia, 
commonly associated with chronic renal failure 
and cancer chemotherapy.  
Amgen 4.4  
Revenue collection is expressed as in 1 year (billion). 
Table 4. Top ten pharmaceutical products world wide based on yearly revenue collection. 
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3.4 Global pharmaceutical market  
The global pharmaceutical market grew to $808 billion in 2009, at a compound annual 
growth rate of 9.3% between 1999 and 2009. Year-on-year growth in the global 
pharmaceutical market decreased to 4.6% in 2009, largely as a result of cost containment in 
the US and major European markets and the impact of several blockbuster patent expiried 
in 2008 and 2009. Almost 125 pharmaceutical drugs generated more than 1 billion USD in 
global sales. The leading therapy areas by global pharmaceutical sales in 2009 were CNS 
with a 15.8% market share and cardiovascular with 14.5%. The CNS pharmaceutical market 
will decrease from $127.8 billion in 2009 to $118.5 billion in 2014. The major five Germany, 
France, Italy, Spain and the UK, together accounted for over 60% of all European 
pharmaceutical sales. The global pharmaceutical market is expected to earn over a trillion 
dollar in revenues by 2012 according to "Global Pharmaceutical Market Forecast to 2012”. 
These include the shift of growth from the developed markets to the emerging ones, 
increasing focus on biotech-based drugs, fewer new drug approvals, and a strong growth in 
the prevalence of generics (Global market, 2012). 
4. Role of pharmaceutical technology 
4.1 Dosage form of modern medicine 
In general, drugs are not administered as pure chemical substance alone rather given 
formulated preparation as medicines. With appropriate additives or excipients in the 
formulation, drug is administered to human body. The main objective of the using additives 
to prepare various dosage forms is to obtain the optimum therapeutic action. Dosage forms 
also contributed for the development of modern pharmaceutical industry. Currently 
available important dosage forms are shown in Table 5 (York, 2007).  
 
Route of 
administration  Dosage forms 
Oral Tablets, capsules, powder, granules, emulsion, suspension, 
syrup, solution 
Topical  Cream, pastes, lotions, ointments, gels, solution, transdermal 
patches, topical aerosol 
Rectal Ointment, Suppositories, creams, powder, solutions 
Parenteral Injections (solution, suspension emulsion), implant 
Inhalation Aerosols, spray, gases 
Nasal Solution, inhalation, spray 
Eye Solution, ointment, cream 
Ear Solution, suspension, ointment, creams 
Table 5. Currently available some important doses form of the modern medicines. 
During early development of drugs, most of the drugs given to patient were in the powder 
form and route of administration was oral. It was difficult to administered right amount. 
The first aspirin powder was formulated in the tablet form. This gave new direction to the 
pharmaceutical industries. Today, more and more patient compliance adopted and choice of 
formulation is based on the patient interest. The flavour was introduced on the drug to 
make more palatable. Drug compound in the tablet or in the capsules is coated in order to 
make palatable and slow dissolution to carry the drug substance into the targeted sites. 
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Same drug can be administered by different route to obtain different therapeutic effects. For 
example drug substance administered i.v. route comes in blood circulation within a few 
seconds, while it might take minutes to hours if it is taken by oral route depending on the 
type of formulation. Some coated tablets or capsules deliver the drugs into the blood 
circulation after several hours. Therefore the design of formulation and selection of route 
can provide the controlled bioavailability of the drugs. The knowledge of pharmaceutical 
technology optimized the therapeutic value of the drugs and reduced the side effect. The 
major routes used for the administration of drugs are shown diagrammatically in Figure 4.  
 
Fig. 4. Schematic diagram showing major routes of administration in the human body and 
drug metabolism. 
4.2 Drug target 
In general, drug formulation is administered through one of the routes into the human 
body. To obtained the therapeutic effect of the drug, all pharmacological properties of the 
drugs have to be explained. The drug action mechanisms of most of the modern drugs are 
well explained otherwise it would not be approved by the authority. The stability and 
activity of the drugs are thoroughly monitored from the point of administeration to the 
point of elimination. In order to understand the drug action, the action of drugs on 
particular receptor or enzymes is studied. In spite of growing knowledge on gene analysis 
and understanding, almost half of the drugs efficacies are targeted to the receptor on the 
cells. The drugs bind directly or activate certain protein to bind on the receptor molecule 
which results the cascade of the molecular activity inside the cells to cure disease. Some of 
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the pathophysiological conditions appear because of the excessive or decreased production 
and activity of certain enzyme. Thus drugs are targeted to particular enzyme activity. 
Almost close to one third of the drugs available today are targeted to enzymes. Some major 
targets of the modern drugs for their action are shown in Figure 5 (Drews, 2000). 
Understanding on drug target to DNA, nuclear receptor and ion channel are relatively low 
at present, however, it is expected to increase in the future.  
 
 
Fig. 5. Biochemical classes of drug targets of current therapies. 
4.3 Drug discovery 
Drug discovery project is a great challenge of knowledge, human resources and money. In 
order to make one successful medicine, generally it needs up to 14 years to complete all 
steps if all the steps remain successful according to our present knowledge. In mean time it 
might cost up to a total of 800 million US dollar investment. A general outline of drug 
discovery strategy is presented in Figure 6. According to the current trend, a new drug is 
hardly marketed even after detail analysis of almost 100000 small molecules in initial study. 
 
 
Fig. 6. Schematic diagram of drug discovery strategy. 
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In spite of huge effort there is still high percentage drug candidates fails to reach as new 
drug agent (NDA). There are several factors which contribute to the failure of drugs. In 
general most of the drug candidate showing potent pharmacological property in in vitro and 
animal experiment fails during the translation to human. It is mainly due to difficulty to 
study the pharmacokinetic properties in human. A general trend of failure rate during the 
drug discovery is presented in Table 6. 
 
Failure rate Percentage 
Poor pharmacokinetic properties in human 39 
Clinical efficacy 29 
Toxicity and adverse effects 21 
Commercial limitations   6 
Table 6. Failure rate (%) of drug development process at different stages. 
4.4 Preclinical strategy of drug discovery 
Almost 70 to 80% of the total budget and two third of the total time period in the drug 
discovery project are consumed by the clinical trial. Therefore in order to enhance the 
success rate, preclinical strategy should be strong, effective and logical. A diagrammatic 
outline for preclinical strategy is given in figure 7. 
 
Fig. 7. Diagrammatic representation of preclinical strategy in drug development. 
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4.5 Evaluation for bioavailability 
In addition to technological advancement, most of the drugs are taken from oral route and 
dosage form is tablet. Even a good drug cannot exert its therapeutic beneficial effects if it is 
not reaching its target site in the body at an appropriate concentration for a sufficient 
length of time. Swallowing a pharmacologically active chemical compound in the tablet or 
any other form by the patient might not be enough to obtain medicinal value.  
Several other factors have to be considered: 
 In the stomach, the tablet might not be disintegrated, the drug might not be released 
from the dosage form 
 Drug might not be soluble into the gastrointestinal fluids 
 If drug is not soluble, in general, it will not be absorbed and will not be able to reach the 
targeted site passing through the epithelial membranes of gastrointestinal tract  
 Some drugs chemically or enzymatically degrade in the stomach or might have gastric 
irritation 
 In some case the drug dissolves very fast and is absorbed very quickly from the 
gastrointestinal tract, in spite of high plasma concentration peak and fast elimination, 
such drug type might have short duration of action so drug has to taken very frequently 
and leading to strong fluctuations in plasma concentration. 
 Some drugs can not be delivered by the oral route as they are metabolized in the 
intestine and/or liver, before reaching to systemic circulation 
 Some drugs may have strong side effect profile, which may prohibit efficient treatment. 
Drugs administered through the oral route must pass through the intestinal barrier to reach 
into the circulatory system. Therefore the drugs which are easily absorbed in gastrointestinal 
track with high permeation and remains stable during circulation in different tissue especially 
in the liver and kidneys provide optimum bio-availability. In general, the chemical nature of 
the drugs determines its bioavailability. Bioavailability of the drugs can be predicted mainly 
by the molecular size and hydrogen bonding capacity (Lipinsky Rule of 5).  
 
Fig. 8. Classification of drugs based on the solubility and permeability. 
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Based on the permeability and solubility, the drug substance can be classified into four 
groups (Figure 8). In case of Class I drugs (high solubility and high permeability) the 
desired bioavailability can easily be reached and the role of formulation will be minimum. 
In case of Class IV drugs (low solubility and low permeability), it is very difficult to attain 
sufficient bioavailability. But in case of Class II or Class III drugs because of the 
improvement of formulation, bioavailability can be enhanced by increasing solubility or 
permeability.  
For those drug candidates having low solubility or low permeability, by the simple structure 
modification or use of additives the bioavailability can be increased. A flow chart scheme to 
enhance the bioavailability is give in Figure 9. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. Flowchart showing to increase the bioavailability. 
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4.6 Multifunctional pharmaceutical nano-carriers drug delivery 
Drug discovery is very expensive and time consuming process. In addition to this, it is not 
sure that the successful candidate will appear at the end. Therefore the research on 
development of drug, especially the delivery system to enhance the bioavailability will 
make more fruitful therapeutic outcome. The development of new drug-delivery 
technologies also made the existing drug more useful. In the present book, the nano-carrier 
as delivery system is discussed in brief.  
Nano-carrier drug delivery is mainly focused to those drugs which are potent 
pharmacologically but it could not be utilized fully because of toxicity (side effect) or less 
efficacy due to low bioavailability. In general, less soluble or less permeable drugs can not 
reach to optimum concentration in the systemic circulation. Therefore these classes of drugs 
are easily packed into the lipid nano-particles in the form of liposome or micelle. Because of 
the drug encapsulation inside the lipid molecule cluster, the physical properties of the drug 
molecules dominated by the lipid cluster particle and therefore lipid molecule cluster serves 
as nano-carrier and drug molecule can be delivered to the targeted site. Nano-particle of 
lipid encapsulated with drug molecules can easily be solubilised and penetrated into the 
cell.  
There are already several drugs based on nano-carrier delivery formulations. A good 
example of nano-carrier delivery is liposomal formulation of amphoteracin B. Amphoteracin 
B has a broad spectrum of activity and is a drug of choice for life threatening invasive fungal 
infections, including disseminated candidiasis, aspergillosis and protozoal infection 
affecting the internal organ (Viscerel leishmaniasis). However, its use is compromised by 
associated adverse side effects.  
But because of nano-carrier delivery liposomal formulation three products such as 
AmBisome (a small unilameller liposomes formulation with the size of 80 nm, composed of 
hydrogenated soy phosphatidyl choline, cholesterol, disteroyl phosphatidyl glycerol and 
amphotericin B in a 2:1:0.8:0.4 molar ratio with α-tocopherol), Abelecet (composed of 
amphotericin B, dimyristoyl phosphatidyl choline and dimyristoyl phosphatidyl glycerol in 
a 1:1 drug-to-lipid molar ratio with sizes is up to 1.6-11 μm) and Amphotec (containing 
amphotericin B in a complex with cholesteryl sulphate at a molar ration (1:1) with the 
particle size of 100-140 nm) are commercialized. Lipid-based nano-carrier formulations are 
found to be superior in clinical efficacy.  
Based on the lipid type and physical condition, the size of particles, nature of the particles 
can be designed. In addition one or more desired ligands can me inserted to drug 
encapsulated nano-particle which allows the drug molecule to be delivered into the targeted 
sites in controlled manner. The additional ligands might be monoclonal antibody (binds to 
specific site), polyethylene glycan (remains longer time in circulation), binding with heavy 
metal (allows to trace the particle), cell penetrating peptide (allows the particle to penetrate 
into the cells), DNA binding (allows the DNA to be delivered) and magnetic nano-carrier (to 
trace the particles) (Figure 10).  
These one or more ligands can be incorporated in the same particles therefore multi-
functions of nano-carriers can be achieved together with the delivery of the drugs. Already 
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the first generation of multifunctional nano-carriers is developed. For example, the nano-
carrier type (B+C) having immunospecific and PEG ligands, should have ability to carry the 
drug molecule to the immunospecific cells where ligand binds and deliver the drugs and 
PEG allows the nano-carrier to remain longer hours in the systemic circulation (Figure 11).  
The future medicine will be the nano-particles packed with several ligands which will be 
able to carry the drug molecules to particular targeted cell with monoclonal antibody and 
penetrated the cell membrane and required drug can easily be delivered without interfering 
with the circulatory system and other tissues or biomolecules (Figure 12). Such smart drug 
delivery will reduce the side effect and enhance the drug efficacy. This will be the 
foundation of ‘Intelligent Therapeutics’ of future drug formulation. 
 
 
 
 
 
 
 
 
 
 
  A  B  C  D  E 
 
 
 
 
 
  F  G 
 
 
 
 
Fig. 10. Diagrammatic representation of nano-carrier designed for the pharmaceutical purpose. 
A: Traditional nano-carrier; B: Targeted nano-carrier (Immunospecific); C: Long circulating 
nano-carrier (PEG protected); D: Contrast nano-carrier (for imaging); E: Cell-penetrating nano-
carrier; F: DNA-carrying  nano-carrier; G: Magnetic nano-carrier. 
+
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Fig. 11. Diagrammatic representation of first generation multifunctional nano-carriers. 
 
 
 
 
 
 
Fig. 12. Dream multifunctional nano-carrier. 
5. Conclusion 
Happy life, healthier life and long life have been remained as the goal of human life 
philosophy. Modern medicine, at least in a part, contributed to humanity to become more 
prosperous and more civilized. In fact, in searching of more effective medicine in the quest 
of healthier and longer lives, it led to the development of basic chemistry and human 
biology. The traditional agricultural based human demographical society transformed to 
industrialisation and pharmaceutical industries have great role for the globalization of the 
world. Moreover, modern medicine discovery and development not only supported to 
healthier and longer life but also encouraged to prosper the development of the modern 
science and technology.  
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